# **Overview of ICRP Committee 2**

## **Doses from Radiation Exposure**

2 2nd October 2013 . Abu Dhabi

John Harrison Public Health England, UK

## Committee 2 Remit

**Committee 2** develops references models and data, including dose coefficients, for the assessment of exposures to radiation from both internal and external sources

- Large programme of work to replace all published dose coefficients following :

**Publication 103** The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP 37 (2-4) 2007

# Constraints, reference levels

| BANDS OF                  | CHARACTERISTICS  |
|---------------------------|--|
| PROJECTED DOSE            | AND  |
|                           | REQUIREMENTS   |
| Greater than 20 - 100 mSv | Exceptional situations. Benefit on a case-by-case basis.<br>Information, training and individual monitoring of workers,<br>assessment of public doses. |
| Greater than 1 - 20 mSv   | Individual direct or indirect benefit. Information, training and either individual monitoring or assessment.   |
| 1 mSv or less             | Societal benefit (not individual).<br>No information, training or individual monitoring. Assessment<br>of doses for compliance.                        |



## C2 Publications since 2007

**Publication 107** Nuclear Decay Data for Dosimetric Calculations. Ann ICRP 38 (3) 2008

**Publication 110** Adult Reference Computational Phantoms. Ann ICRP 39 (32) 2009

**Publication 116** Conversion Coefficients for Radiological Protection Quantities for External Radiation Exposures. Ann ICRP 40 (2-5) 2010

**Publication 119** Compendium of Dose Coefficients based on ICRP Publication 60. Ann ICRP 41 (Supp1) 2012

**Publication 123** Assessment of Radiation Exposure of Astronauts in Space. Ann ICRP 42 (4) 2013

# **Planned** publications

## Phantoms and radiations transport calculations

- "Radiation Transport for Adult Phantoms (Adult SAFs)
- "Pediatric Reference Computational Phantoms + SAFs
- "Pregnant Female and Fetus Reference Computational Phantoms + SAFs

### Internal dose coefficients

"Occupational Intakes of Radionuclides, Parts 1 - 5

- "Internal Dose Coefficients for Members of the Public, Pts 1 & 2
- " In utero Internal Dose Coefficients for Maternal Intakes
- "Breast-feeding Infant Internal Dose Coefficients for Maternal Intakes

### **External dose conversion coefficients**

" External Dose Coefficients for Members of the Public Use of Effective Dose

# Phantom development

### **Stylized Phantoms**

Organ / body contours defined by 3D mathematical surface equations

### **Voxel Phantoms**

Organs and body tissues defined by groupings of 3D arrays of tagged image volume elements

### **Hybrid Phantoms**

Organ / body contours defined by NURBS or polygon mesh surfaces







# ICRP Adult Reference Computational Phantoms – Voxel Based

## ICRP Publication 110 Ann ICRP 39 (2) 2009





## ICRP Computational Phantoms – Pediatric Developed using NURBS and PM Surface Modeling



## **Skeletal Dosimetry Models**

#### Craniofacial bones



## Occupational Intakes of Radionuclides OIR Part 1 Introduction

**OIR Part 2** H, C, P, S, Ca, Fe, Co, Zn, Sr, Y, Zr, Nb, Mo, Tc

OIR Part 3 Ru, Sb, Te, I, Cs, Ba, Ir, Pb, Bi, Po, Rn, Ra, Th, U

OIR Part 4 Lanthanides and Actinides

OIR Part 5 F, Na, Mg, K, Mg, Ni, Se, Mo, Tc, Ag

INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION ICRP C2 seminar. Rio de Janeiro, Brazil, 12 September 2012

## Human Respiratory Tract Model, Pub 66 (1994)



## Al Retention: new data



## Systemic model for lodine





#### Former model (ICRP 1994)

Figure 5-2. Structure of the biokinetic model for systemic iodine used in this report.

#### **OIR model**

# OIR dose coefficients for cobalt

|  | Effective d      | ose coefficient  | ts (SV Bd-1)     |
|--|------------------|------------------|------------------|
|  |                  |                  |                  |
|  | <sup>57</sup> Co | <sup>58</sup> Co | <sup>60</sup> Co |
| Inhaled particulate materials (5 µm AMAD aerosols) |                  |                  |                  |
| Type F, cobalt nitrate, chloride                   | 3.3E-10          | 1.4E-09          | 1.1E-08          |
| Type M, all unspecified forms                      | 1.0E-09          | 4.3E-09          | 2.7E-08          |
| Type S, cobalt oxide, FAP, PSL                     | 2.4E-09          | 6.6E-09          | 1.7E-07          |
| Ingested materials                                 |                  |                  |                  |
| $f_{\rm A}$ = 0.1, all chemical forms              | 2.4E-10          | 1.2E-09          | 7.6E-09          |
| $f_{\rm A}$ = 0.05, insoluble oxides               | 1.7E-10          | 9.8E-10          | 4.8E-09          |

INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION

# Bioassay data for <sup>60</sup>Co : inhalation of 1 Bq Type M



## Radon doses

## **Epidemiological** approach

Divide risk per WLM
by risk per Sv
= Sv per WLM

## **Dosimetric approach**

Calculate using models

## Epidemiological approach

## USING 5 x 10<sup>-4</sup> per WLM lung cancer risk

| Workers | 4.2 x 10 <sup>-2</sup> Sv <sup>-1</sup> | 12 mSv WLM <sup>-1</sup> |
|---------|---|--------------------------|
|         | 5.7 x 10 <sup>-2</sup> Sv <sup>-1</sup> | 9 mSv WLM <sup>-1</sup>  |

## **Publication 65 values**

Workers

**Public** 

5 mSv WLM<sup>-1</sup> 4 mSv WLM<sup>-1</sup>



# Geometric Model of Airway for Dosimetry



INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION

25481

## Bronchial (BB) Wall Dosimetry



### Alveolar-interstitium



# Factors affecting dosimetric calculations

## " Aerosol characteristics

- Unattached fraction
- Size distribution
- " Equilibrium factor
- <sup>‴</sup> Breathing rate
- " Absorption of progeny
- " Systemic biokinetics



# Equilibrium factor, F

F is a measure of the degree of dis-equilbrium between radon gas and its progeny

| 1 = 1                 |     | Γ=0.                  | .5  |
|-----------------------|-----|-----------------------|-----|
|                       |     |                       |     |
| <sup>222</sup> Rn gas | 1.0 | <sup>222</sup> Rn gas | 1.0 |
| <sup>218</sup> Po     | 1.0 | <sup>218</sup> Po     | 0.6 |
| <sup>214</sup> Pb     | 1.0 | <sup>214</sup> Pb     | 0.3 |
| <sup>214</sup> Bi     | 1.0 | <sup>214</sup> Bi     | 0.2 |

The value of F depends on the ventilation rate :

|  | Natural ventilation |
|--|---------------------|
|  | Forced ventilation  |



#### Porstendörfer 2001, Marsh *et al* 2002

Lung tissue weighting cf. relative detriment - Effect on Rn-222 progeny dose

Mine E per WLM = 12 mSv

Lung  $w_T$ = 0.12Relative detriment for lung= 0.286all adults

*E* per WLM potentially = 29 mSv all adults

## Lung dose apportionment - Effect on Rn-222 progeny dose

### Lung apportionment factors



MineE per WLM= 12 mSvUsing average lung dose= 0.6 mSv

## Membership 2013 - 17

John Harrison (Chairman) UK François Paquet (Vice-Chairman) France Wesley Bolch (Secretary) USA

Mike Bailey UK Vladimir Berkovski Ukraine Luiz Bertelli USA Doug Chambers Canada Marina Degteva Russia Akira Endo Japan John Hunt Brazil Chan Hyeong Kim (S Korea) Rich Leggett USA Jizeng Ma China Dietmar Noßke Germany Nina Petoussi-Henss Germany Frank Wissmann Germany

## Task Groups of Committee 2



TG 21. Internal Dosimetry (INDOS) François Paquet

TG 79 . Effective Dose

John Harrison

TG 90. Dose Coefficients for External Environmental Exposures

Nina Petoussi-Henss

## Summary

C2 has large programme of work to provide new dose coefficients

Biokinetic and dosimetric modelling is world leading, with scientific as well as protection applications

C2 leading in explaining use of Effective dose

Strong interactions between committees, including C2 membership of Task Groups

### www.icrp.org

